Literature DB >> 11369814

Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth.

P Muñiz1, A Fortuño, G Zalba, M A Fortuño, J Díez.   

Abstract

BACKGROUND: Torasemide and furosemide are diuretics that inhibit the Na(+), K(+), 2Cl(-) co-transporter localized in cells from the ascending limb of the loop of Henle. The effects of torasemide and furosemide on cell growth induced by angiotensin II (Ang II) were investigated in cultured vascular smooth muscle cells (VSMCs) obtained from the aorta of adult spontaneously hypertensive rats (SHR).
METHODS: Cell growth was determined by DNA and protein synthesis as measured by [3H]thymidine and [3H]leucine incorporation, respectively. Proliferation of VSMCs was measured using a non-radioactive colorimetric cell proliferation assay.
RESULTS: Ang II (10(-7) M) signficantly increased DNA and protein synthesis and cell proliferation in VSMCS: These effects were completely abolished by the Ang II type 1 receptor antagonist irbesartan (10(-6) M). Ang II-induced [3H]leucine incorporation was reduced in a dose-dependent way by torasemide (IC(50) value: 7.7+/-0.8x10(-7) M) but not by furosemide. Neither torasemide nor furosemide modified Ang II-stimulated [3H]thymidine incorporation or proliferation in VSMCs.
CONCLUSIONS: These results indicate that torasemide, but not furosemide, inhibits Ang II-induced protein synthesis in VSMCs from SHR. Thus, it is suggested that the capacity of torasemide to block this trophic action of Ang II in rat VSMCs is not mediated by inhibition of the Na(+), K(+), 2Cl(-) co-transport mechanism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369814     DOI: 10.1093/ndt/16.suppl_1.14

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

Review 1.  A reappraisal of loop diuretic choice in heart failure patients.

Authors:  Jonathan Buggey; Robert J Mentz; Bertram Pitt; Eric L Eisenstein; Kevin J Anstrom; Eric J Velazquez; Christopher M O'Connor
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.

Authors:  Ali Ahmed; Ahsan Husain; Thomas E Love; Giovanni Gambassi; Louis J Dell'Italia; Gary S Francis; Mihai Gheorghiade; Richard M Allman; Sreelatha Meleth; Robert C Bourge
Journal:  Eur Heart J       Date:  2006-05-18       Impact factor: 29.983

3.  Linking binge alcohol-induced neurodamage to brain edema and potential aquaporin-4 upregulation: evidence in rat organotypic brain slice cultures and in vivo.

Authors:  Kumar Sripathirathan; James Brown; Edward J Neafsey; Michael A Collins
Journal:  J Neurotrauma       Date:  2009-02-11       Impact factor: 5.269

4.  A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure.

Authors:  Ali Ahmed; James B Young; Thomas E Love; Raynald Levesque; Betram Pitt
Journal:  Int J Cardiol       Date:  2007-08-16       Impact factor: 4.164

5.  β-Arrestin-mediated Angiotensin II Signaling Controls the Activation of ARF6 Protein and Endocytosis in Migration of Vascular Smooth Muscle Cells.

Authors:  Ricardo Charles; Yoon Namkung; Mathieu Cotton; Stéphane A Laporte; Audrey Claing
Journal:  J Biol Chem       Date:  2015-12-24       Impact factor: 5.157

6.  Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide.

Authors:  Vera von Dossow; Claudia Spies; Hannes Schenk; Sabine Schlesinger; Christian von Heymann
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.

Authors:  Basile Gravez; Antoine Tarjus; Ruben Jimenez-Canino; Soumaya El Moghrabi; Smail Messaoudi; Diego Alvarez de la Rosa; Frederic Jaisser
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.